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        ABSTRACT 
BACKGROUD 
HIV has placed a large burden of disease in developing countries. HIV drug resistance is 
inevitable  due to selective pressure. Computer algorithms have been proven to help in 
determining optimal treatment for HIV drug resistance patients. One such algorithm is the 
ANRS gold standard interpretation algorithm developed by the French National Agency for 
AIDS Research AC11 Resistance group. 
OBJECTIVES 
The aim of this study is to investigate the possibility of improving the accuracy of the ANRS 
gold standard in predicting HIV drug resistance. 
METHODS 
Data consisting of genome sequence and a HIV drug resistance measure was obtained from 
the Stanford HIV database. Machine learning factor analysis was performed to determine 
sequence positions where mutations lead to drug resistance. Sequence positions not found 
in ANRS were added to the ANRS rules and accuracy was recalculated. 
RESULTS 
The machine learning algorithm did find sequence positions, not associated with ANRS, but 
the model suggests they are important in the prediction of HIV drug resistance. Preliminary 
results show that for IDV 10 sequence positions where found that were not associated 
with ANRS rules, 4 for LPV, and 8 for NFV. For NFV, ANRS misclassified 74 resistant profiles 
as being susceptible to the ARV. Sixty eight of the 74 sequences (92%) were classified as 
resistance with the inclusion of the eight new sequence positions. No change was found 
for LPV and a 78% improvement was associated with IDV. 
CONCLUSION 












            CHAPTER ONE 
           INTRODUCTION 
This chapter deals with the background of the Human Immunodeficiency virus (HIV) and the need for the 
machine learning algorithms to detect HIV drug resistance in developing countries
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                      INTRODUCTION 
1.1 Introduction to HIV worldwide and South Africa 
HIV continues to be the major health concern. Worldwide, there is an estimated 36.9 Million 
(including 2.6 million children) that are infected with HIV with a global prevalence of 0.8% 
(UNAIDS 2015) many still living with AIDS (Health Systems Trust, 2011b). In 2014, there were 
roughly 2 million new HIV infections, of which 220,000 were children. Most of these children live 
in sub-Saharan Africa and were infected via maternal to child transmission (UNAIDS 2015). 
HIV/AIDS places a major burden on the resources of developing countries (Health Systems Trust, 
2011a). It is the leading cause of death in sub-Saharan Africa (Campbell et al., 2008) and is one the 
major epidemics in South Africa. Among adults aged 15–49, HIV prevalence for women is over 
23% compared to 13% among men, a gender difference of more than 10%. Women aged 15 to 24 
have an HIV incidence rate more than four times that of men, with a 4.5% incidence of HIV among 
Black African women (HSRC 2012). 
There are currently almost 5.6 million infected with HIV in South Africa, which is approximately 
11% of  the South African population (AIDS Committee of Actuarial Society of South Africa, 
2008).  It is also estimated that there are almost 500 000 patients who exhibit AIDS defining 
conditions (Health Systems Trust, 2011a). There are an estimated 24.7 million (23.5–26.1 million) 
people living with HIV in sub-Saharan Africa, nearly 71% of the global total. Ten countries— 
Ethiopia, Kenya, Malawi, Mozambique, Nigeria, South Africa, Uganda, the United Republic of 
Tanzania, Zambia and Zimbabwe— account for 81% of all people living with HIV in the region 
and half of those are in only two countries— Nigeria and South Africa (HIV/AIDS, 2014). 
South Africa has the biggest and most high profile HIV epidemic in the world, with an estimated 
6.3 million people living with HIV in 2013. In the same year, there were 330,000 new infections 
while 200,000 South Africans died from AIDS related illnesses (Simbayi et al., 2014). Province 
wise, Kwazulu-Natal has been reported the highest percentage of HIV prevalence. The rates of HIV 







                  PROVINCE  HIV PREVALENCE RATE 
Eastern Cape 11.6 





Northern Cape 7.4 
North West 13.3 
Western Cape 5.0 
Table 1: shows the prevalence rate of HIV in different provinces in South Africa (South African 
National HIV Prevalence, Incidence and Behaviour Survey, 2012) 
1.2 The Human Immunodeficiency virus  
Human Immunodeficiency virus (HIV) belongs to the family retroviridae and genus lentivirus. 
These are positive-stranded RNA viruses. Following infection, the single-stranded RNA genome is 
reverse-transcribed into double-stranded DNA into the host cell (Cann and Karn, 1989). The 
resulting double-stranded DNA is subsequently irreversibly integrated into the host genome. These 
HIV virions have spherical shape morphology of 100-120nm. The virus is composed of lipid bilayer 
membrane which envelopes a dense nucleocapsid (Cann and Karn, 1989). This nucleocapsid is 
formed by capsid protein p24 and contains two single stranded RNA copies, the reverse 
transcriptase, the viral protease and the other accessory and regulatory protein and also some 
cellular factors.These destroy the human immune system over a long period of time by invading T 
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helper cells. There are two types of HIV: HIV I and HIV II, both of which believed to be originated 
in Africa (Wilson et al., 2002). These were at first only found in primates in the form of Simian 
Immunodeficiency virus but zoonotic infections, through infected meat, caused it to transfer to 
humans (Wilson et al., 2002). 
1.2.1 HIV I 
HIV I was first detected in the late 1970s (Gallo  and Montagnier 2003)HIV I is believed to be 
originated from Central Africa, and 95% of all HIV infection can be attributed to HIV I (Quinn, 
1998). HIV-1 is subdivided into four groups representing four separate introductions of simian 
immunodeficiency virus (Akhilesh et al.) into humans:   M (major), N (non-major), O (outliers) and 
P (most similar to SIV) (Faria et al., 2014) 
Currently group M is subdivided into nine subtypes or clades: A, B, C, D, F, G, H, J, K based on 
variations in genetic sequence characteristics (Kanki et al., 1999, Robertson et al., 2000). It is, 
however, possible for viruses from different subtypes to form mosaic genomes called circulation 
recombinant forms (CRFs) (Abecasis et al., 2007) 
Most African patients are infected with M type with subtype C, whereas the European patients are 
infected with M type with subtype B (Robertson et al., 2000). 
1.2.2   HIV II 
HIV II arose from Western Africa and it was first identified in the mid-1980s (De Cock and Brun-
Vézinet, 1989) Until 2000 it was only confined to West Africa, but due to immigration of people 
all-round the world it is found elsewhere as well. HIV II is also further divided into 5 types from A 
to E. It has a slower infectivity and progression rate compared to HIV-I (De Cock and Brun-
Vézinet, 1989)  The patients who progress slowly and has more indolent course can be deciding 
factor to monitor for  HIV-2–infection (Campbell-Yesufu and Gandhi, 2011). 
1.2.3 Mode of infection 
There are different modes of HIV transmission, blood transmission being the most common. Table 









1. Vaginal Intercourse 0.1% 
2. Anal Intercourse 1% 
3. Percutaneous exposure 0.3% 
4. Needle Sharing 1% 
5. Mother-to-child  20%-40% 
6. Blood transfusion 100% 
Table 2: Shows the type of exposure and the associated probability of infection (Adapted from 
1.(Boily et al., 2009), 2. (Vitinghoff et al., 1999), 3. (Del Romero et al., 2002), 4. (Baggaley et al., 
2006), 5. (Townsend et al., 2008), 6. (Baggaley et al., 2006). 
1.2.4  HIV Management 
There is no cure for HIV, but HIV infection can be effectively managed with antiretroviral 
(Marques et al.) drugs usually in the form of highly active antiretroviral therapy (HAART), which 
comprises of a regimen of three drugs from at least two of the following five drug classes (Mitton, 
2000a, Bartlett and others, 2004, Pierret, 2007, Beerenwinkel and others, 2002). Reverse 
transcriptase inhibitors (RTI) which consists of Nucleoside Reverse Transcriptase Inhibitors (NRTI) 
and Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTI), Protease inhibitors (PI), Integrase 
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inhibitors (Tomimatsu et al.), Fusion inhibitors (FI) and Entry Inhibitors (EI) (Arts and Hazuda, 
2012) 
1.2.5 Mechanism of action of Anti-retroviral drugs 
Nucleoside transcriptase inhibitors (NRTI’s) work by competing with the nucleoside for active 
binding sites. If the drug successfully binds to an active site, then the transcription or copying of the 
sequence is hindered (Fowler et al., 2014) Non- nucleoside reverse transcriptase inhibitors NNRTI’s 
inhibits the transcription in a non-competitive manner. It binds to any location other than active 
sites in an attempt to stereotypically obstruct the sequence from passing over the active sites of the 
reverse transcriptase enzyme (Usach et al., 2013) 
Protease inhibitors (PI’s) work by inhibiting the action of the protease enzyme. It impedes the 
cleavage of the large gap-pol polyprotein into active virion by binding to the active pocket-like site 
of the protease enzyme and this causes the formation of a non-infectious and immature virion 
(Ghosh et al., 2016) 
Integrase Inhibitors inhibit the action of the integrase enzyme. It prevents the virus from inserting 
it’s vDNA into the hosts cell DNA. This is accomplished by blocking the active sites required by 
the integrase enzyme, thus preventing the insertion (Mesplède et al., 2014) 
Fusion Inhibitors (FI) prevent the replication of the HIV from outside the host cell by blocking 
fusion. Fusion inhibitors work by preventing the hair-pin bend action that allows the HIV to be 
closer to the host cell. Thus because the HIV cannot get close to the host cell, no fusion can take 
place (Chong et al., 2016) 
Entry Inhibitors (EI’s) work by halting the HIV from binding to the gp120 receptor by competing 
for this binding site. This prevents the HIV from binding to the co-receptor (gp41). Without the 









Figure 1;The above figure shows the potential or current target for anti-retroviral drugs in HIV life 
cycle.  (A) Schematic of the HIV-1 life cycle in a susceptible CD4+ cell. (B) Time frame for 
antiretroviral drug action during a single-cycle HIV-1 replication. Adapted from (Arts and Hazuda, 
2012). 
1.2.6 HIV drug Resistance 
Various factors influence the management of HIV/AIDS.  Some factors include poor treatment 
regimen prescribed by the physician, WHO stage and progression of the disease, levels of drug 
concentration achieved, patient adherence to the treatment, drug resistance, and toxic effects of the 
drug (Clavel  and Hance 2004) Drug resistance is arguably the most critical aspect of treatment and 
three common reasons that lead to the development of HIV antiretroviral drug resistance are high 
replication rates, selective pressure and initial infection by resistant strains of HIV. Thus it is 
inevitable that drug resistance will become a reality in most patient’s treatment (Vercauteren and 
Vandamme, 2006). 
There are various means of measuring HIV drug resistance. The use of computer algorithms is one 
of the methods which is gaining popularity in developing countries. These algorithms take various 
attributes as inputs, and predict a measure of resistance to HIV drugs. ANRS is one example of such 
algorithms (Gilks et al., 2006) 
1.3 ANRS Algorithm 
One widely used computer based interpretation algorithm was built by the French National Agency 
for AIDS Research AC11 Resistance group and is called the Nationale de Recherches sur le SIDA 
(ANRS) (AC11 Resistance group, 2013). ANRS is seen as a gold standard in interpreting HIV drug 
resistance using mutations in the genomes. ANRS classifies ARV resistance according to three 
levels: susceptible, intermediate, and resistant. “Susceptible” indicates that a particular ARV drug 
will be effective against HIV; “intermediate” indicates that the ARV drug is partially effective; and 
if the ARV is not effective at all, it is classified “resistant” (Liu et al., 2008) 
This algorithm is mainly based on correlation between drug resistance and virological outcome of 
patients who fail ARV treatment. The algorithm is based on a linear combination of mutations. If a 
particular mutation or a group of mutations are is present in the genome, the algorithm returns a 
resistance profile applicable to that particular sequence e.g. if the mutation A98S  is present in the 
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genome,  resistance to the NVP is deduced, were as a E138K mutation will indicate intermediate 
resistance to the NVP drug (Meynard et al., 2002b)  
Compounded to the burden of disease, healthcare is moving towards personalized medicine 
(Ginsburg and McCarthy, 2001) This paradigm of healthcare consists of services provided based on 
individual criteria rather than a set of generalized symptoms. The management of HIV/AIDS is also 
becoming personalized (De Luca et al., 2004, Frentz et al., 2010, Yashik and Maurice, 2012). Thus 
the added burden of timely access to information, representative computer algorithms, shortage of 
adequately trained staff etc. becomes more evident in developing countries. 
The use of computer algorithms in personalized medicine is becoming more popular (Vercauteren 
and Vandamme, 2006, Pasomsub et al., 2010). However, in many cases, like ANRS these 
algorithms are created in silos, uses the knowledge and perceptions of a few specialists in the field, 
and in specific environments. There are thus many opportunities to improve these algorithms 
(Snoeck et al., 2006a, Vergne et al., 2006). 
Given the background for the study, the aim of this study is to improve on the HIV drug resistance 
prediction ability of the ANRS algorithm using machine learning techniques. The research 
questions of the study and to answer the questions theobjectives made are as follows: 
I.  Is it possible to determine important HIV drug resistant associated mutations using machine 
learning? 
Objective I. . Create machine learning algorithms to determine the relationship between mutations 
and the resistance in the genome of HIV patients i.e. create an association matrix. 
II. Is it possible to improve the current accuracy of the ANRS gold standard? 
Objective II.  Compare the association matrix mutations to the matrix associated with resistance as 
per ANRS gold standard rules. 
III. Is it possible to improve the current sensitivity, specificity, positive predictive value and 
negative value of the ANRS gold standard? 
Objective III.  Determine if the ANRS gold standard can be improved with the incorporation of the 




Computer based algorithms are usually based on an experts’ understanding of the domain, available 
datasets that are used for machine learning and understanding of published literature. This has led to 
the creation of many different interpretation algorithms, which produce different resistance 
measures even if applied to the same resistance profile. The main aim of this study is to improve the 
efficiency of predicting HIV drug resistance by ANRS. This chapter described the background 













                  
          
      CHAPTER TWO  













The literature review explores the three dominant themes of research questions i.e. the mechanism 
of drug resistance in HIV treatment, possibility to determine important HIV drug resistant 
associated mutations using machine learning and improving  the current sensitivity, specificity, 
positive predictive value and negative value of the ANRS gold standard. Major scientific databases 
like PubMed, google scholar and science direct were used for doing the literature review. 
2.1 Introduction 
Although combination therapy for HIV infection represents a triumph for modern medicine, 
eradication for HIV is still not possible due to the latency of the virus (Katlama et al., 2013). Both 
preventive and therapeutic vaccines are currently being tested. HIV is effectively controlled by 
antiretroviral which is introduced at some point between clinical latency and progression to AIDS. 
Several factors are considered before starting ARV like the CD4 counts. Prophylactic treatment can 
be done in post exposure; this reduces the chances of the virus progression. Also these drugs are 
used to prevent mother to child transmission of the virus. ARV are managed in highly anti-retroviral 
therapy (HAART), the drugs are usually a combination of three drugs from the class of possible 
five drugs
 
(Beerenwinkel et al., 2005, Mitton, 2000b, Tang and Shafer, 2012).  
 
Factors that influence treatment of HIV/AIDS with antiretroviral include poor treatment regimen 
prescribed by the physician, WHO stage of the disease which is related to the progression of the 
disease, levels of drug concentration achieved, how strictly the patient adheres to the regimen, drug 
resistance, and the toxic effects of the drug (Richman and Staszewski, 2000). Drug resistance is 
arguably the most critical aspect of treatment. 
 
HIV drug resistance is caused inevitably due to selective pressure (viruses that happen to survive 
the drug are favoured, and resistant virus strains evolve within the patient) which can happen 
sometimes in just few weeks as ARV is introduced. Not only ARV’s but other things like 
pesticides, industrialization and antibiotics also confer selective pressure. HIV virus represents an 
interesting case as its speed of evolution has changed considerably over time (Feder et al., 





The ability of HIV to continue to mutate and reproduce even during the treatment is called HIV 
drug resistance. Three common reasons that lead to the development of HIV antiretroviral drug 
resistance are high replication rates, selective pressure and initial infection by resistant strains of 
HIV. Thus it is inevitable that drug resistance will become a reality in most patient’s treatment 
(Vercauteren and Vandamme, 2006). 
 
2.2 Factors that lead to the development of HIV drug resistance 
2.2.1 High replication rate 
 The HIV-replicates itself 1010 times in 24 hours  (Moodley, 2006). The minimum duration of the 
HIV-1 life cycle in vivo is 1.2 days on average, and that the average HIV-1 generation time, defined 
as the time from release of a virions until it infects another cell and causes the release of a new 
generation of viral particles, is 2.6 days (Perelson et al., 1996). It is estimated that in an individual 
with the active disease, all possible combinations of nucleotides in the genome are generated in a 
single day. Due to a high replication rate and lack of error checking in the polymerase enzyme, the 
HIV has the highest known mutation rate of any organism. It has been shown that HIV-1 virus has 
extremely high mutation rate of (4.1 ± 1.7) × 10
−3
 per base per cell, the highest reported for any 
biological entity (Cuevas et al., 2015b). 
Mutations occur when there is a change in the nucleotide sequence of the genome of any organism. 
It is the result of any unrepaired damage which has been there in either DNA or the RNA of the 
cell. These are usually caused by radiation or chemical reactions. Mutations may or may not 
produce observable changes in the characteristics (Lodish et al., 2000). 
Mutations can result in several different types of changes in the sequences. It can either have effect 
in the gene, where it doesn’t allow the gene to function properly or it can have absolutely no effect. 
Mutations can cause a lot of DNA and RNA to duplicate, which causes evolving of new genes. 
There are two main kinds of mutations. Small scale mutations are a kind of mutations where a small 
gene in one or few nucleotide is affected. Small scale mutation is further classified into point 
mutation, insertion and deletions. Point mutation can further be broken into silent, missense and 
nonsense mutations (Lodish et al., 2000) 
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The other major mutation type is the large scale mutation, where the chromosome structure is 
affected. Large scale mutation is further divided into amplification, deletion, mutation which 
juxtaposes already separated DNA and loss of heterozygosity (Lodish et al., 2000)The virus mutates 
by adding, subtracting or substituting one or more nucleotides at various positions along the 
genome sequence. The high mutation rate (4.1 ± 1.7) × 10-3 per base per cell (results in the 
formation of quasi-species/variants and minority sub-populations (Cuevas et al., 2015a) Similar to 
other organisms, the virus’s main purpose is to survive. It does this by encouraging the survival of 
the mutated virus that will survive in patient’s body and pays less attention to those that will not 
survive (survival of the fittest) (Wilson D et al., 2002).  
2.2.2 Selective pressure 
The rate of resistance caused by the selective pressure is determined by residual replication and the 
genetic barrier of the drug (David, 2009) The first factor, residual replication, refers to the potency 
of the drug regimen. When under the selective pressure of a single drug regimen, it stands to reason 
that, a large number of mutants will escapes from the ARV and will replicate (http://i-
base.info/category/publications/) However, if a two drug regimen is used i.e. a slightly increased 
drug regimen potency, the rapid evolution of the drug resistant variants is initiated. This results in 
more drug resistant variants escaping and replicating. Fortunately, under very high drug regimen 
potency (three or more drugs from at least two different drug classes) viral replication is minimized 
to such an extent that the likelihood of resistance emerging is diminished. Such drug combinations 
increase the second selective pressure factor called the generic barrier (Feder et al., 2015). 
The second factor is due to the nature of the drug itself. If the genetic barrier is low it signifies that 
very few mutations are "sufficient to cause resistance". Examples of such drugs are lamivudine and 
NNRTI’s. Other drugs have a high genetic barrier, implying that many mutations are required to 
induce resistance. Indinavir and Abacavir are examples of drugs with a high genetic barrier 
(Moutouh et al., 1996) In a high genetic barrier environment, variants that do escape have a very 
small advantage over the wild-type virus because it must “accumulate multiple additional mutations 
before out -growth can occur”. This implies that a person under ARV treatment for extended 
periods will eventually develop drug resistance. HAART treatment is lifelong and adherence of 
around 95% is required in order to maintain low levels of virus and reduce the development of drug 
resistant quasispecies (Carvalho and Pinto, 2016) 
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2.2.3 Initial infection 
Individuals may also acquire drug resistance during initial infection as a result of primary 
transmission. In developed countries, it is estimated that 10% of the circulating viruses contain at 
least one drug resistance mutation (Clavel  and Hance 2004) 
It was reported in 2009, that 37% of patients that required ARV treatment actually received ARV 
drugs in South Africa (Adam and Johnson, 2009). Due to the high replication rates of the virus, 
selective pressure caused by the ARV drugs and initial infection by resistant strains of HIV, it is 
inevitable that drug resistance will become a concern in the treatment of HIV/AIDS infected 
patients.  
2.3 Measuring HIV drug resistance 
HIV drug resistance is normally measured by phenotypic or genotypic testing. Both these are 
usually wet chemistry tests that comprise of isolating the HIV from an infected individual and then 
using standard wet-chemistry techniques to measure and represent concentration or resistance 
directly (Hirsch et al., 1998) 
2.3.1 Phenotypic testing 
Phenotypic assays use direct in-vitro method of predicting resistance which is based on IC50 score 
(it is the concentration of drugs which is required to kill half the virus of the sample virus 
population which is wild type). It also requires growing HIV in a sterile and controlled laboratory 
environment. Here ARV is used to kill the 50% of the virus and then the two are compared. These 
comparisons are used in predicting the resistance (John et al., 2000) 
 
         Not Resistant,   IC50 < susceptible score; 
Resistance= Susceptible resistance,  susceptible score < IC50 < resistant score 
                     Resistant,    IC50 > resistant score 
 
2.3.2 Genotypic testing 
HIV virus genome when mutated causes chemical and stereotypical changes, which cause the ARV 
to be less effective. Genotypic assays use chemicals to test for resistance by determining the 
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presence of mutation. This array requires complex mutation and genotypic variation patterns. 
Genotypic assay is a kind of resistance test which uses chemical methods to get the presence of any 
mutation or variation of mutations. Therefore, this kind of mutation requires interpretation of 
complex mutation and genotypic patterns. This also requires inference of phenotype, using rules 
and algorithms. These rules and algorithms mainly apply to subtype prevalent (Durant et al., 1999) 
Phenotypic assays are time consuming, expensive and each test is done with just single ARV. 
Therefore, genotypic assays are more used as it is much cheaper and faster (Jiamsakul et al., 2016). 
Interpreting the results of the mutations present found in the genome sequence is difficult and is a 
source of contention. Computer based interpretation algorithms may be created to determine HIV 
drug resistance using mutations in the genome. There are generally two types of these interpretation 
algorithms (Yashik and Maurice, 2012)  One consists of predetermined rules, created by human 
experts, which associate particular mutations to resistance profiles or measures.  For example, a 
typical expert rule is that a mutation in the 215
th
 amino acid in the reverse transcriptase sequence, 
where tyrosine replaces threonine, causes resistance to ARV Zidovudine.  The other consists of 
using artificial intelligence or also called machine learning, to determine associations between 
mutation in the genome and resistance profiles based of large amounts of data (Hales et al., 2006)  
There are two groups in which the interpretation algorithm has been classified (Yashik and 
Maurice, 2012) 
 1. One based on the domain knowledge, which means it is based on the fact that certain 
combinations of known mutations cause unequivocal resistance. 
 2. The other is not based on the predefined domain knowledge; it includes machine learning and 
statistical methods. 
2.4 Interpretation algorithm based on domain knowledge 
This interpretation algorithm is accepted by most of the scientific community. All the computational 
decisions concerning resistance are based on known mutation-resistance rules which are already 
published in scientific literature. REGA, ANRS Stanford’s HIV db and RetroCram are the examples 
of such algorithms (de Oliveira et al., 2005). 
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REGA and ANRS have 3 different levels of resistance classification, resistance, intermediate and 
susceptible (Singh and Mars, 2014). Susceptible means that a particular ARV will be effective 
against HIV. Intermediate means the particular drug will be partially effective against HIV. 
Resistant means that the particular drug will be ineffective and lead to virological failure (Singh and 
Mars, 2014).On the other hand Stanford’s HIV db output consists of (AC11 Resistance group) a list 
of penalty scores for each antiretroviral (Marques et al.) resistance mutation in a submitted 
sequence, (2) estimates of decreased NRTI, NNRTI, protease and integrase inhibitor susceptibility, 
and (3) comments about each ARV resistance mutation in the submitted sequence (Tang et al., 
2012). 
 
ANRS is a French National Agency for AIDS Research, which has an algorithm which is used to 
check the HIV drug resistance. ANRS is an interpretation algorithm which is based domain 
knowledge. This is much more accepted by the scientific community. ANRS has been regarded as 
the gold standard among all algorithm used for HIV drug resistance (de Oliveira et al., 2005). 
 
2.5   Interpretations algorithms not based on known domain knowledge 
There are many machine learning algorithms applied to finding a predictable correlation between 
genotyping and phenotypic data. These data are known as virtual phenotyping. 
Virtual phenotyping is getting more popular and Kuritzkes  supports the virtual phenotype as a tool 
for viral genotype (Singh and Mars, 2014) Here are few successful algorithms -Neural Network 
-Support Vectar Machines  
-Linear regression models 
-Decision Tree 
-Ridge Regression. 
The above mentioned algorithms were primarily developed using different sets of datasets, subtypes 
and from non-treated (drug naïve) and treated patients (Singh and Mars, 2014). 
 Interpretation algorithm based on domain knowledge is regarded as gold standard and widely used 
by the scientific communities as they are based on scientific and published interaction between 
certain mutation or combination of mutations (Singh and Mars, 2014). 




Published algorithm against gold 
standard 
Creator  Accuracy  
AntiRetroScan  Zazzi M. (2008)  89.4 
Associative classification Srisawat  A and Kijsirikul  B (2008) 84.1 
MLP(∆Energy)  Bonet I et al (2007) 85.8 
MLP (Energy)  Bonet I et al (2007) 88.6 
RBNN  Bonet I et al (2007) 93.6 
Committee Neural Network   Draghici S and Potter R (2003) 
 
78 
Decision tree  James R (2004) 76 
Dr Seqan Garriga C and Menendez A (2006) 
 
43 
Geno2Pheno  Beernwinkel N. et al (2003)  
KNN James R (2004) 49 






Table 3: The summary of the comparisons of the results from the previous studies.  
The above table also indicates that although interpretation algorithms have been researched for a 
few years, improvement is possible. There may be a time when these electronic interpretation 
algorithms may completely replace the laboratory phenotyping testing 
Drug resistance is a very important factor influencing the failure of current HIV therapies. The 
ability to predict the drug resistance of HIV protease mutants may be useful in developing more 
effective and longer lasting treatment regimens. Drăghici and  Potter best combination yielded an 
average of 85% coverage and 78% accuracy on previously unseen data. This was more than two 
times better than the 33% accuracy expected from a random classifier. DR_SEQAN which is an 
easy to use off-line application that provides expert advice on HIV genotypic resistance 
interpretation with an improved reported accuracy of 43%.  
Previous studies have shown a maximum accuracy of 93.6 % and the lowest as 29%.Hence, it 
clearly shows possibility of using machine learning  imprvovment in the accuaracies of ANRS in 
predicting HIV drug resistance. 
 
Retrogram Garriga  C and Menendez A (2006) 
 
61 
Stanford HIV-db algorithm authors implementation  
Stanford HIV-db algorithm  Garriga  C and Menendez A (2006) 29 
Stanford HIV-db algorithm Zazzi M. (2008) 84.3 
Visible Genetics/Bayer Diagnostics 
Guidelines 6.0 
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THE USE OF MACHINE LEARNING TO IMPROVE THE EFFECTIVENESS OF ANRS   
IN PREDICTING HIV DRUG RESISTANCE 
 3.1 Manuscript format 
This chapter consists of a paper that has been formatted according to ‘African Journal of 
Biomedical Research’. 
Shrivastava A, and Singh Y The use of machine learning to improve the effectiveness of 
ANRS in predicting HIV drug resistance. Original Research paper 
 
3.2 Introduction 
This chapter describes the use of machine learning to improve the effectiveness of ANRS in drug 
resistance. Genomic mutations can be used in computer based algorithms to detect HIV drug 
resistance. Computer based algorithms are generally based on available datasets and published 
literature. Therefore, there are always chances of improvement. 
3.3. Materials and Methods 
Data consisting of genome sequence and a HIV drug resistance measure was obtained from the 
Stanford HIV database. Machine learning factor analysis was performed to determine sequence 
positions where mutations lead to drug resistance. 
3.4 Results 









The use of machine learning to improve the effectiveness of ANRS in predicting         
HIV drug resistance 
   Shrivastava A
1




Department of Telehealth, Nelson R Mandela School of medicine, University of 
KwaZulu Natal, South Africa 
Corresponding author; singhyashik@gmail.com 






















HIV drug resistance is inevitable due to selective pressure. Computer based interpretation 
algorithm, built by the French National Agency for AIDS Research AC11 Resistance 
group, is called the Nationale de Recherches sur le SIDA (ANRS) and is the gold standard 
in interpreting HIV drug resistance using mutations in the genomes. Computer based gold 
standard interpretation algorithms are usually based on an experts’ understanding of the 
domain and available datasets and so there may be discrepancies and areas of improvement.  
The aim of this study is to investigate the possibility of improving the accuracy of the 
ANRS gold standard in predicting HIV drug resistance. Genome sequence and a HIV drug 
resistance measure were obtained from the Stanford HIV database 
(http://hivdb.stanford.edu/). Feature selection was used to determine the most important 
mutations associated with resistance prediction (association matrix). These mutations were 
added to the ANRS rules and difference in prediction ability between ANRS and ANRS 
with the association matrix was measured. Preliminary results show that for IDV 10 
sequence positions where found that were not associated with ANRS rules, 4 for LPV, and 
8 for NFV. For NFV, ANRS misclassified 74 resistant profiles as being susceptible to the 
ARV. Sixty eight of the 74 sequences (92%) were classified as resistance with the inclusion 
of the eight new sequence positions. No change was found for LPV and a 78% 
improvement was associated with IDV. The above study shows that there is significant 
improvement in the prediction ability of ANRS gold standard. 
Key words: ANRS, Artificial Intelligence, interpretation algorithms, ARV resistance 
prediction, machine learning 
Running title 













Developing countries are characterized by poor infrastructure and limited resources. The 
World Health organization has indicated that the current financing strategy, in many 
developing countries, does not meet the requirements for universal health care coverage. 
Thus, developing countries struggle under the burden of human immunodeficiency virus 
(HIV), Tuberculosis and Malaria (Yashik and Maurice, 2012). HIV is an incurable disease 
which affects the functioning of the immune system of a human over a long period of time. 
There are two known strains of the HIV, i.e. HIV-1 and HIV-2 (Wilson et al., 2002, The 
EuroGuidelines Group for HIV Resistance, 2003). The majority of HIV infection is due to 
HIV-1. 
There are currently almost 6.4 million infected with HIV in South Africa, which is 
approximately 12.2% of the South African population (AIDS Committee of Actuarial 
Society of South Africa, 2011, Simbayi et al., 2014). Swaziland has a HIV infection 
prevalence of 26%, Botswana 25% and Lesotho 24% (Central Intelligence Agency, 2012).  
The burden of HIV in Africa is seen in the contrast with the prevalence of HIV in 
developed countries.  France and Spain has a prevalence of 0.4% while Netherland has a 
prevalence of 0.2%. It is also estimated that there are almost 500 000 patients who exhibit 
AIDS defining conditions in South Africa (Health Systems Trust, 2011b). 
HIV is managed by highly active antiretroviral therapy, which comprises of antiretroviral 
(Marques et al.) drugs from protease inhibitors, reverse transcriptase inhibitors; integrate 
inhibitors, fusion inhibitors, and entry inhibitors. However the success of managing HIV 
with ARV’s is dependent on the actual treatment, stage of the disease, drug potency, patient 
adherence, achievable drug concentrations, drug resistance and  toxic effects of the drugs 
(Richman and others, 2000, Singh and Mars, 2012b). Of these factors drug resistance is 
crucial, and is defined as the diminished ability of antiretroviral drugs to reduce the HIV 
viral load adequately (Singh and Mars, 2012b) 
HIV drug resistance is inevitable due to selective pressure facilitated by the presence of  
ARVs during the management of HIV, high replication errors of the virus and initial 
infection (The EuroGuidelines Group for HIV Resistance, 2003) . Thus the ability to easily 
determine drug resistance is vital in the treatment of the HIV positive patients. HIV drug 
resistance is normally tested using phenotypic test (Meynard et al., 2002b). 
In brief, phenotypic tests work by analyzing the concentration of ARV that is required to 
reduce the reproduction of a laboratory grown sample of the HIV that has infected a 
specific patient by 50%. The ratio of this concentration over the concentration required 
when using the wild type (original) HIV virus is called the IC50.  The IC50 score is 
compared to cutoff values obtained from literature and is thus characterized as being either 
resistant to ARV drugs, susceptible to ARV drugs or intermediate resistance to the ARV 
drugs.   Although the IC50 score is seen as the absolute measurement, laboratory based 
tests are relatively expensive, time consuming, susceptible to error and each test detects 
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resistance to a single drug and thus many tests are required to determine multiple drug 
resistances (Bartlett and others, 2004). 
Electronic computerized algorithms (Toor et al., 2011) may also be used to determine ARV 
drug resistance, and have many advantages over phenotype testing. Computer based 
genotype interpretation algorithms usually determine mutations in the patient’s pol gene 
and uses this information to determine which ARV drugs the patients are resistant to. 
Literature has associated mutations with particular resistance profiles.  These computer 
based tests are faster and cheaper than phenotypic tests. 
One widely used computer based interpretation algorithm was built by the French National 
Agency for AIDS Research AC11 Resistance group and is called the Nationale de 
Recherches sur le SIDA (ANRS).  ANRS is seen as a gold standard in interpreting HIV 
drug resistance using mutations in the genomes.  ANRS classifies ARV resistance 
according to three levels: susceptible, intermediate, and resistant. “Susceptible” indicates 
that a particular ARV drug will be effective against HIV; “intermediate” indicates that the 
ARV drug is partially effective; and if the ARV is not effective at all, it is classified 
“resistant”. 
. This algorithm is mainly based on correlation between drug resistance and virological 
outcome of patient who fail ARV treatment. The algorithm is based on a linear combination 
of mutations. If a particular mutation or a group of mutations are is present in the genome,  
the algorithm returns a resistance profile applicable to that particular sequence e.g.if the 
mutation A98S  is present in the genome,  resistance to the NVP is deduced, were as a 
E138K mutation will indicate intermediate resistance to the NVP drug (Meynard et al., 
2002a) 
Each rule consists of a Boolean expression. For example, an ANRS rule for abacavir 
(version 13, July 2005) states: “If there are five or more of the following RT mutations 
(M41L, D67N, L74V, M184V/I, L210W, T215Y/F), report resistance to abacavir.” Both 
systems contain interpretations for all available antiretroviral drugs, including the fusion 
inhibitor (Liu and Shafer, 2006). 
The ANRS system bases its interpretations almost entirely on genotype outcome studies  
and the ANRS has published a large proportion of the studies linking genotype to 
virological outcome, including studies on the genotypic predictors of response to abacavir 
(Katlama et al., 2000),tenofovir(Katlama et al., 2000), didanosine (Masquelier et al., 
2004)and many more. 
Computer based gold standard interpretation algorithms are usually based on an experts’ 
understanding of the domain, available datasets and understanding of published literature. 
There therefore may be discrepancies and areas of improvement. 
The average accuracy for ANRS was 59%,HIV-db 59% and REGA 61% (Singh and Mars, 
2012a).It has been shown that there is no difference between the three algorithms in the 
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accuracies obtained (Poonpiriya et al., 2008). Various other studies (Snoeck et al., 2006b, 
Yebra et al., 2010) have shown there is no difference between accuracies, however, 
accuracy cannot be the sole factor for determining discrepancy between the three 
algorithms .Thus the aim of this study is to use machine learning to see if there can be  
improvements in the effectiveness of ANRS in predicting HIV drug resistance.  
Materials and Methods 
Development of the association matrix 
Machine learning is literally an adaptive process whereby computers can improve by 
experience and analogy. Feature Selection ReliefF, MODTREE Filtering, FCBF Filtering 
and CFS Filtering were used to determine HIV drug resistance. 
Feature Selection Relief is a supervised based on RELIEFF principle. This approach does 
not take into consideration the redundancy of the input attributes. Fast Correlation based 
Filter (FCBF) is a supervised feature selection algorithm based upon a filtering approach i.e 
processes the selection independently from the learning algorithm. This algorithm, unlike 
the ranking approaches takes into consideration the redundancy of the input attribute 
(Bouhamed et al., 2012). Correlation based feature Selection is also a supervised feature 
selection algorithms based upon a filtering approach i.e. processed the selection 
independently from the learning algorithm. The Multivalued Oblivious Decision tree 
(MODTREE ) method is based on the notions of relevance and redundancy, through it does not use 
the same correlation measure, as it rests on the principle of pair-wise comparison. Lallich and 
Rakotomala(1999-2002)designed this (MODTREE) feature selection. The calculation is 
linear in number of observations n, even if the criterion is based on the principle of pair-wise 
comparisons. This makes it operational for processing databases involving a large number of lines. 
The partial correlation is applied to achieve the step-by-step “Forward” selection. It measures the 
correlation degree between two variables X and Y by subtracting the effect of a third variable Z 
(Rakotomalala and Lallich, 2002). 
The open source software used to perform machine learning was Tanagra. Tanagra is a data 
mining suite build around graphical user interface. Tanagra is particularly strong in 
statistics, offering a wide range of uni- and multivariate parametric and nonparametric tests 
(Rajkumar and Reena, 2010). 
The methods used in this paper are divided into three parts: data-processing, development 
of an association matrix, and the determination of the effectiveness of ANRS with the 




Free publically available and de-identified Genotype-Phenotype datasets that consisted of 
approximately 23000 protease gene and 23000 reverse transcriptase gene sequences were 
obtained from the Stanford HIV drug resistance database (http://hivdb.stanford.edu/).  
These datasets were fed in the ANRS algorithm and a resistance measure was obtained for 
each sequence. The ANRS result was then compared to the known resistance measure 
obtained from laboratory test for each sequence, and the accuracy of the ANRS algorithm 
was calculated. 
 
Effectiveness of ANRS with the incorporation of the association matrix 
The association matrix for each drug was added to the rules of the ANRS algorithm. This 
new model was then applied to the testing dataset and the changes in the ability to predict 
HIV drug resistance was analyzed. 
 Results 
The study showed considerable improvement in predicting HIV drug resistance using 
machine learning against gold standard ANRS. Table 1 shows the important mutations that 
contribute to resistance for each of the ARV’s. Table 2 shows the correctly classified 
sequences out of the total sequences and the accuracy in percentage of all the PR ARVs. 
*RS = the sequence was incorrectly classified as resistant instead of susceptible. SR =the 
sequence was incorrectly classified as susceptible instead of resistant. Table3 shows the 
correctly classified sequences out of the total sequences and the accuracy in percentage of 
all the RT ARVs. *RS = the sequence was incorrectly classified as resistant instead of 
susceptible. SR = the sequence was incorrectly classified as susceptible instead of resistant. 
 
Discussion  
Results show that the ANRS gold standard can be improved in predicting HIV drug 
resistance in all ten ARV drugs tested. Table one shows the mutations not present in the 
ANRS algorithm for each of the 10 ARV drugs. Some of the major contributors to 
predicting HIV drug resistance for protease ARV drugs, using the feature selection 
algorithms, were P63, P57, P82, and P69. However, the HIVdb drug resistance database 
has only P82 in its major mutation list. It clearly shows machine learning also picked up 
those mutations that were not listed in the HIVdb database. Similarly P30, P35, P142, and 
P83 were identified as important mutations for RT ARV drugs. The ten most ANRS 
algorithm in order to determine if there is any change to the ability of ANRS to predict 
susceptibility and resistance to ARV drugs.   
An average of 85 PI sequences that were supposed to be interpreted as resistance, were 
classified as susceptible according to ANRS. Adding the rules derived from the machine 
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learning algorithm, results in an 88 ± 7.1% improvement in the overall accuracy. A T-test 
was performed to determine if the improvement was due to random chance, and a p <0.001 
was obtained. This indicates that there is a statistically significant improvement in the 
prediction of susceptibility measures for the five protease drugs.   
An average of 31 PI sequences was wrongly classified as susceptible instead of resistant. 
Adding the rules derived from the machine learning algorithm, results in an 83 ± 12.1% 
improvement in the overall accuracy. A T-test was performed to determine if the 
improvement was due to random chance, and a p < 0.004 was obtained. This indicates that 
there is a statistically significant improvement in the prediction of resistance measures for 
the five protease drugs. 
Nearly 130 sequences were wrongly put under susceptible, which were actually resistant. 
Using the machine learning algorithm rules, results in a 69 ± 10.9% improvement in the 
overall accuracy. A T-test was performed to determine if the improvement was due to 
random chance, and a p value of 0.004 was obtained. This indicates that there is a 
statistically significant improvement in the prediction of resistance measures for the five 
RT drugs 
An average of 147 PI sequences was wrongly classified as susceptible instead of resistant. 
Adding the rules derived from the machine learning algorithm, results in an 80 ± 5.9% 
improvement in the overall accuracy. A T-test was performed to determine if the 
improvement was due to random chance, and a p < 0.004 was obtained. This indicates that 
there is a statistically significant improvement in the prediction of resistance measures for 
the five RT drugs. Table 4 shows the positive predictive value (PPV) and negative 
predictive value (NPV) of all the PR ARVs used in the study. * Z-Score is > 1.98, 
indicating there is a statically significant difference when adding the association matrix. 
Table 5 shows the PPV and NPV of predicting HIV resistance for PR ARV drugs for both 
the ANRS algorithm alone and when the machine learning mutations are incorporated into 
them. The PPV improved by 27% while the NPV improved by 16%. These results show 
that the incorporation of the machine learning mutation does positively influence the ability 
of ANRS to predict RT ARV drug resistance. * Z-Score is > 1.98, indicating there is a 
statically significant difference when adding the association matrix 
Conclusions  
The above study shows that there is significant improvement in the prediction ability of 
ANRS gold standard. On average the ARNS algorithm was improved by 79% ±6.6. The 
positive predictive value improved by 28% and the negative predicative value improved by 
10%.  Some of the major contributors to predicting HIV drug resistance for protease ARV 
drugs, using the feature selection algorithms, were P63, P57, P82, and P69. Similarly P30, 
P35, P142, and P83 were identified as important mutations for RT ARV drugs. These 
indicate that the ANRS gold standard has its limitations, which can be improved. Future 
studies may include using other machine learning algorithms like support vector machines 
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Table 2: The above table shows the correctly classified sequences out of the total sequences 
and the accuracy in percentage of all the PR ARVs. *RS = the sequence was incorrectly 
classified as resistant instead of susceptible. SR =the sequence was incorrectly classified as 
















No. of incorrectly 
classified sequences 





IPV RS 14 1       92.85 
IPV SR 32 3       90.62 
IDV RS 201 47 76.6 
IDV SR 9 3 66.6 
NFV RS 74 6 91.8 
NFV SR 25 6 76 
SQV RS 128 8 93.7 
SQV SR 68 18 83.3 
TPV RS 7 1 85.7 



















ABC RS 55 13 76.36 
ABC SR 206 28 86.4 
DDI RS 165 29 82.42 
DDI SR 165 44 73.33 
EFV RS 233 96 58.79 
EFV SR 131 20 84.73 
NVP RS 170 73 57.05 
NVP SR 177 45 74.57 
TDF RS 25 8 68 
TDF SR 55 10 81.81 
Table 3: The above table shows the correctly classified sequences out of the total sequences 
and the accuracy in percentage of all the RT ARVs. *RS = the sequence was incorrectly 
classified as resistant instead of susceptible. SR = the sequence was incorrectly classified as 











ARV INTIAL  
% PPV 
% PPV WITH 
ASSOSIATION 
MATRIX 
NPV NPV WITH 
ASSOCIATION 
MATRIX 
IDV 70 92* 98 99* 
LPV 97 100* 93 99* 
NFV 88 99* 96 99* 
SQV 74 98* 94 99* 
TPV 0 86* 95 100* 
Table 4: The above table shows the positive predictive value (PPV) and negative predictive 
value (NPV) of all the PR ARVs used in the study. * Z-Score is > 1.98, indicating there is a 





























Table 5 shows the PPV and NPV of predicting HIV resistance for PR ARV drugs for both 
the ANRS algorithm alone and when the machine learning mutations are incorporated into 
them. The PPV improved by 27% while the NPV improved by 16%. These results show 
that the incorporation of the machine learning mutation does positively influence the ability 
of ANRS to predict RT ARV drug resistance. * Z-Score is > 1.98, indicating there is a 
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             SYNTHESIS, CONCLUSION AND RECOMMENDATION  
The high mutation rate of HIV drug under selective pressure leads to drug resistance and treatment 
failure (Cuevas et al., 2015a)  The dissertation provides following important points 
I. The use of current high speed technologies and computational methods has recently contributed 
in predicting HIV drug resistance.  
II. The interpretation algorithms like REGA, HIV-db and Agence Nationale de Recherches sur le 
SIDA  (ANRS)  are logic or decision tree based, however, these were developed using different data 
subsets on experienced and drug niave patients (Yashik and Maurice, 2012).  
III. The key findings of our study are that there are chances of improvement in the gold standard in 
predicting HIV drug resistance, almost an 80 ± 5.9% improvement in the overall accuracy. 
The above study shows that there is significant improvement in the prediction ability of ANRS gold 
standard. On average the ARNS algorithm was improved by 79% ±6.6. The positive predictive 
value improved by 28% and the negative predicative value improved by 10%.  Some of the major 
contributors to predicting HIV drug resistance for protease ARV drugs, using the feature selection 
algorithms, were P63, P57, P82, and P69. Similarly P30, P35, P142, and P83 were identified as 
important mutations for RT ARV drugs. These indicate that the ANRS gold standard has its 
limitations, which can be improved. Future studies may include using other machine learning 
algorithms like support vector machines and Bayesian networks. A larger dataset will be of benefit.  
Conclusion 
The study shows that there are great amount of improvement which can be done in the ANRS. 
Although ANRS is regarded as the gold standard, there are certain rules which can still be 
improved. 
There were quite a few sequences which were note correctly noted in ANRS which can be changed 
to improve the testing of HIV drug resistance. 
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This study can help increase the effectiveness of the HIV treatment throughout the world, especially 
in developing countries. When the resistance is determined beforehand it will certainly give doctors 
a better option for treatment. 
The most challenging portion was data processing and analyzing the results of the machine learning 
algorithms. The sheer volume of the neucliotites that were analysed  in order to create the input 
space possed a lenge. Trying to map a large unprocessed input space into a smaller input space 
created many issues. The smaller input space was required for the machine learning algroithm to 
better map the learning process. However, if the input space was too small, it would have been so 
simplistic to represent the large unprocessed input space. Hence there would have been valuable 
connections and better data points that would have been lost.  
Generally, computer science articles do not process the results of the learning algorithms 
statistically. This was a challenge as very few papers explain how to statistically compare results of 
machine learning.  
This study gave me an appreciation of the statistical components of research, and also allowed me 
to understand the impact of data, data processing and data analysis from a machine learning point of 
view.  
Limitations 
Among the different subtypes, subtype C is predominant in developing countries, however due to 
the availability of data subtype B is most present in developed counties was used in the study. 
Validations of the algorithms were done using publicly available data from Standford University 
HIV db. 
Future recommendations 
Machine learning requires large dataset. As such a larger dataset, particularly with a greater number 
of subtype C will be beneficial. Further investigation is required using other machine learning 
techniques e.g. support vector machine, gene expression, random forest tree. Interpretation may be 
improved by adding interpretation from other algorithms.  
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This will play a huge part economically. As countries with limited resources will not have to waste 
the ARVs. It will help in the treatment of the patient, as it will help the doctors to choose the drugs 
in advance and not the current way of testing different drugs on single patient. 
The most important thing is that developing and economically weak nations will have the benefit of 
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